Sanjay Lakhani, MD
General Practice · Highland Park, MINPI 1700962446
Payments from drug & device makers
Across 122 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$659
- Novo Nordisk$322
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$225
- Otsuka America Pharmaceutical, Inc.$212
- AbbVie$200
- Merck$138
- plus $490 from 13 others
What the payments were for
- Food & beverage$2,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $659 |
| Novo Nordisk | 21 | $322 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $225 |
| Otsuka America Pharmaceutical, Inc. | 9 | $212 |
| AbbVie | 4 | $200 |
| Merck | 8 | $138 |
| GSK | 5 | $100 |
| Pfizer | 5 | $77 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Dexcom, Inc. | 2 | $42 |
| Phadia US Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Gilead | 1 | $23 |
| Cipher Pharmaceuticals US LLC | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$2,245 in reported general payments places this provider in the 90th percentile of 3,051 general practice providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 478 | $306,587 |
| OzempicSemaglutide | 266 | $258,784 |
| MounjaroTirzepatide | 239 | $252,150 |
| FarxigaDapagliflozin Propanediol | 413 | $242,688 |
| Xigduo XrDapaglifloz Propaned/Metformin | 378 | $226,155 |
| TrulicityDulaglutide | 149 | $145,467 |
| EliquisApixaban | 200 | $124,781 |
| JardianceEmpagliflozin | 178 | $107,072 |
| EntrestoSacubitril/Valsartan | 103 | $67,090 |
| LinzessLinaclotide | 102 | $55,041 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $46,736 |
| Tresiba Flextouch U-100Insulin Degludec | 81 | $43,183 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $40,063 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $39,351 |
| RybelsusSemaglutide | 30 | $35,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $13 | $397,617388 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $100 | $319,099515 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $659 | $302,038553 claims |
| Novo NordiskOzempic, Rybelsus | $322 | $294,617296 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $77 | $151,201244 claims |
| NovartisEntresto | $14 | $67,090103 claims |
| AbbVieLinzess | $200 | $55,041102 claims |
| GileadBiktarvy | $23 | $46,73612 claims |
| MerckJanuvia | $138 | $15,79929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,051 general practice providers in Michigan.
Other general practice in Highland Park
- Anil PrasadTaylor$1.7M
- Sadeer DaoodDearborn$1.1M
- Shakib HalabuWest Bloomfield$1.1M
- Dennis FasbinderAnn Arbor$758K
- Christian GrothAnn Arbor$283K
- Kevin BoneSaginaw$125K
- David JulianiRochester Hills$106K
- Marie FluentAnn Arbor$106K
- Howard KormanRoyal Oak$93K
- Hans SchwarzSterling Heights$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.